Ilmarinen Mutual Pension Insurance Co Has $3.06 Million Holdings in Biogen Inc. $BIIB

Ilmarinen Mutual Pension Insurance Co lowered its position in shares of Biogen Inc. (NASDAQ:BIIB) by 27.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 17,400 shares of the biotechnology company’s stock after selling 6,600 shares during the quarter. Ilmarinen Mutual Pension Insurance Co’s holdings in Biogen were worth $3,062,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. WPG Advisers LLC boosted its position in Biogen by 417.9% during the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 117 shares during the last quarter. First Horizon Corp acquired a new position in Biogen during the 4th quarter worth approximately $30,000. GoalVest Advisory LLC acquired a new position in Biogen during the 4th quarter worth approximately $35,000. Accredited Wealth Management LLC boosted its position in Biogen by 1,233.3% during the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 185 shares during the last quarter. Finally, Elevation Wealth Partners LLC boosted its position in Biogen by 412.8% during the 4th quarter. Elevation Wealth Partners LLC now owns 200 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 161 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Analyst Ratings Changes

BIIB has been the subject of a number of recent research reports. The Goldman Sachs Group increased their price objective on shares of Biogen from $231.00 to $238.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Evercore initiated coverage on shares of Biogen in a research note on Friday, May 15th. They set an “outperform” rating for the company. Freedom Capital upgraded shares of Biogen from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 1st. TD Cowen increased their price objective on shares of Biogen from $175.00 to $215.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Finally, Royal Bank Of Canada increased their price objective on shares of Biogen from $222.00 to $227.00 and gave the stock an “outperform” rating in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $215.81.

Biogen Trading Down 0.2%

NASDAQ BIIB opened at $196.00 on Friday. Biogen Inc. has a 12 month low of $121.05 and a 12 month high of $205.97. The company has a market cap of $28.94 billion, a PE ratio of 21.03, a PEG ratio of 1.73 and a beta of 0.19. The stock has a 50 day moving average of $186.66 and a 200-day moving average of $182.21. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last issued its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The business had revenue of $2.48 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same period last year, the business posted $3.02 EPS. Biogen’s revenue was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, equities research analysts anticipate that Biogen Inc. will post 14.18 EPS for the current fiscal year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.